Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2000-04-04
2003-03-11
Goldberg, Jerome D. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
57
Reexamination Certificate
active
06531482
ABSTRACT:
Throughout this application various publications are referenced by numbers within parentheses. Full citations for these publications may be found at the end of the specification immediately preceding the claims. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.
BACKGROUND OF THE INVENTION
Angiotensin II (AII) is now known to act on the systemic vasculature and at several sites within the renal microcirculation with effects on vascular tone and vascular growth and extracellular matrix accumulation (1-6, 40). Angiotensin I converting enzyme inhibitor (ACEI) has been used as a primary tool to control hypertension, increase organ blood flow and preserve organ structure. However, while ACEI causes vasodilation, including within the renal circulation, its specific effects, to decrease resistance of both glomerular afferent and efferent arterioles, can reduce glomerular capillary pressure and therefore filtration. The renin angiotensin system (RAS) has been postulated to be linked to other vasoactive substances, notably bradykinin, which may account for part of ACEI-induced vasodilatation (7-12). Assessment of the specific effects of endogenous AII on the renal circulation has been limited by this uncertain non-specific action of ACEI, and also by the partial agonist effects of previously available AII analogues. Recently, the availability of both a specific nonpeptide AII type 1 receptor antagonist (AIIRA) which lacks agonist effects (13, 14), and a specific bradykinin receptor antagonist (15) has circumvented these difficulties. These developments are important, since it is frequently necessary to inhibit RAS effects in patients, including vasoconstriction, vascular growth and extracellular matrix accumulation.
Thus, there is a great need for a method of inhibiting RAS while maintaining or increasing GFR levels and protecting the kidney from structural injury. The invention provides that this can be accomplished by antagonizing AII type 1 vascular receptor in a patient. Further, this invention provides that these beneficial effects on the kidney can be accomplished independently of AII type 1 vascular receptor antagonist effects on systemic blood pressure or other cardiac pathologies.
SUMMARY OF THE INVENTION
This invention provides a method of and compositions for increasing or maintaining glomerular filtration rate while preserving renal structure in a patient comprising administering an angiotensin II type 1 vascular receptor antagonist to the patient, independent of its effects on systemic blood pressure. The invention provides that, by administering the AII type 1 receptor antagonist, blood flow to the kidney can be improved without sacrificing intraglomerular pressure and therefore glomerular filtration and that even with this enhanced glomerular pressure and filtration, renal structure is preserved. Also provided is a method of screening AII type 1 receptor antagonists for the ability to maintain or increase glomerular filtration rate while decreasing mesangial matrix accumulation comprising the steps of administering the antagonist in an animal model characterized by decreased glomerular filtration rate and increased mesangial matrix accumulation and selecting the compounds that increase glomerular filtration rate while decreasing mesangial matrix accumulation.
REFERENCES:
patent: 5049565 (1991-09-01), Chen et al.
patent: 5087702 (1992-02-01), Chen et al.
patent: 5210079 (1993-05-01), Carini et al.
patent: WO 92/10182 (1992-06-01), None
Chang et al.FASEB5(Part 111):6993 (Abstr) 1991.
Kon et al. “Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition”,Kidney Internat'l44:545-550, Sep. 1993.
Peten et al. “High dose ACE inhibitor (ACEI) or ANGII receptor antagonist (ANTII RI) therapy does not improve glomerulosclerosis (GS) in mice transgenic for growth hormone (GH MICE)”,J. Am. Soc. Nephrol. Abstract vol. 4(3), p. 780, Sep. 1993.
Kakinuma et al. “Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure”,Kidney Internat'l42(1):46-55, Jul. 1992.
Chan et al. “Renal-specific actions of angiotensin II receptor antagonism in the anesthetized dog”Am. J. Hypertens. 5:354-360, Jun. 1992.
Kivlighn et al. “Antihypertensive efficacy and effects on renal function of L-158,809: A nonpeptide orally active angiotension II antagonist”HypertensionAbstract 19(1):I-135, Jan. 1992.
Kivlighn et al. “Antihypertensive efficacy and effects on renal function in the conscious spontaneously hypertensive rat (SHR)”FASEB JournalAbstract vol. 5(5), p. A1576, Mar. 19, 1991.
Bovee et al. “Effects of the nonpeptide angiotensin II receptor antagonist DuP 753 on blood pressure and renal functions in spontaneously hypertensive PH dogs”,Am. J. Hypertens. 4:327S-333S, Apr. 1991.
Takeda, et al.Kidney International, 42:1713-1719, 1992.
Fogo et al.Kidney International42:770-774, 1992.
Awazu et al.J. Amer Soc. Nephrology, 1:1253-1258, 1991.
Kon and BadrKidney International, 40:1-12, 1991.
Kon et al.Kidney International. 37:1487-1491, 1990.
Burnier et al. “Salt-Dependent Renal Effects of an Angiotensin II Antagonist in Healthy Subjects”Hypertension22:339-347, 1993.
Tsunoda et al. “Hypertensive Effect of Losartan, a Nonpeptide Angiotensin II Receptor Antagonist, in Essential Hypertension”Am J of Hypertens6(1):28-32, Jan. 1993.
Weber, Michael A. “Clinical Experience With the Angiotensin II Receptor Antagonist Losartan”Am J Hypertens5(12) Part 2:247S-251S, Dec. 1992.
Duncia et al. The Discovery of DuP 753, a Potent, Orally Active Nonpeptide Angiotensin II Receptor Antagonist,Med Res Rev12(2):149-91, Mar. 1992.
Mimran et al. “Converting Enzyme Inhibitors and Renal Function in Essential and Renovascular Hypertension”Am J of Hypertens4(1) Part 2:7S-14S, Jan. 1991.
Prescott et al. “Angiotensin-Converting Enzyme Inhibitor Versus Angiotensin II, At1Receptor Antagonist: Effects on Smooth Muscle Cell Migration and Proliferation After Balloon Catheter Injury”Am J of Pathology139(6):1291-1296, Dec. 1991.
Siegl et al. “In Vitro Pharmacology of a Highly Potent and Selective Nonpeptide Angiotensin II (A11) Receptor Antagonist: L-158, 809”Antihypertensive Drugs I, Abstract No. 6994, A1576, 1991.
Kamper, Anne-Lise “Angiotensin Converting Enzyme (ACE) Inhibitors and Renal Function”Drug Safety6(5):361-370, 1991.
Chiu et al. “Nonpeptide Angiotensin II Receptor Antagonists. VII. Cellular and Biochemical Pharmacology of DuP 753, an Orally Active Antihypertensive Agent”J Pharmacol Exp Ther252(2):711-718, Feb. 1990.
Hricik et al. “Angiotensin-Converting Enzyme Inhibitor-Induced Renal Failure: Causes, Consequences, and Diagnostic Uses”J. Am. Soc. Nephrol. 1(6):845-858, 1990.
Kalra et al. “Renovascular Disease and Renal Complications of Angiotensin-Converting Enzyme Inhibitor Therapy”Quarterly Journal of Medicine77(282):1013-1018, Oct. 1990.
Speirs et al. “Postmarketing Surveillance of Enalapril. II: Investigation of the Potential Role of Enalapril in Deaths with Renal Failure”BMJ297(6652):830-832, Oct. 1988.
Slaughter et al. “Canine Essential Hypertension: Probable Mode of Inheritance”J. of Hypertens, 4(Suppl. 5):S170-S171, 1986.
Hostetter et al. “Cardiorenal Hemodynamics and Sodium Excretion in Rats with Myocardial Infarction”Am J Physiol, 245(1):H98-103, Jul. 1983.
Brenner et al. “Dietary Protein Intake and the Progressive Nature of Kidney Disease: The Role of Hemodynamically Mediated Glomerular Injury in the Pathogenesis of Progressive Glomerular Sclerosis in Aging, Renal Ablation, and Intrinsic Renal Disease”N Engl J of Med, 307(11):652-659, Sep. 9, 1982.
Fogo Agnes
Ichikawa Iekuni
Kon Valentina
Goldberg Jerome D.
Needle & Rosenberg P.C.
Vanderbilt University
LandOfFree
Method and compositions for maintaining glomerular... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and compositions for maintaining glomerular..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and compositions for maintaining glomerular... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3081115